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ABSTRACT
G-quadruplex ligands exert their antiproliferative
effects through telomere-dependent and telomere-
independent mechanisms, but the inter-relationships
among autophagy, cell growth arrest and cell death
induced by these ligands remain largely unexplored.
Here, we demonstrate that the G-quadruplex ligand
20A causes growth arrest of cancer cells in culture
and in a HeLa cell xenografted mouse model. This
response is associated with the induction of senes-
cence and apoptosis. Transcriptomic analysis of 20A
treated cells reveals a significant functional enrich-
ment of biological pathways related to growth arrest,
DNA damage response and the lysosomal pathway.
20A elicits global DNA damage but not telomeric
damage and activates the ATM and autophagy path-
ways. Loss of ATM following 20A treatment inhibits
both autophagy and senescence and sensitizes cells
to death. Moreover, disruption of autophagy by dele-
tion of two essential autophagy genes ATG5 and
ATG7 leads to failure of CHK1 activation by 20A
and subsequently increased cell death. Our results,
therefore, identify the activation of ATM by 20A as
a critical player in the balance between senescence
and apoptosis and autophagy as one of the key
mediators of such regulation. Thus, targeting the
ATM/autophagy pathway might be a promising strat-
egy to achieve the maximal anticancer effect of this
compound.
INTRODUCTION
G-quadruplexes (G4) are non-canonical DNA or RNA
structures found in guanine-rich regions of the genome (1).
G4 structures are formed by stacking of two or more G-
quartets and are further stabilized by monovalent cations.
G4-prone motifs are enriched in telomeres, promoters and
the first introns of genes (2). Evidence for G4 formation in
cells comes from studies using DNA structure-specific anti-
bodies, in vivo nuclear magnetic resonance, and small com-
pounds capable of selective binding to G4 and from anal-
ysis of genomic instability (for a review: (3)). Compounds
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that bind toG4 are calledG-quadruplex ligands (G4L), and
the most promising compounds exhibit exquisite selectivity
for this unusual structure (for a review: (4)). G4L were ini-
tially developed as telomerase inhibitors, and some G4Ls
have antiproliferative effects that are associated with stabi-
lization of the telomeric G4 structures and telomere erosion
(5,6).
Evidence suggests that antiproliferative effects of certain
G4Ls result from telomere-independent mechanisms. For
example, the majority of G4-antibody foci are actually not
found at telomeres (7), and a number of G4Ls alter the ex-
pression of genes, such as theKRAS and c-MYC oncogenes,
that contain G4 motifs in their promoters (for a review on
G4 in promoters: (8)). In addition, some G4Ls may act by
targeting RNAG4 (for recent reviews on G4 RNA: (9,10)).
As a general mechanism, G4Ls promote the DNA damage
response (DDR) (11), which ultimately leads to senescence
(a permanent growth arrest) or, when the damage is left un-
repaired, cell death (12). These properties make G4Ls at-
tractive for cancer therapy. In addition, some G4Ls are able
to activate the p53/p21 pathway, which is implicated in the
regulation of DDR, senescence and cell death (13,14). It is
not clear, however, what determines whether cells undergo
senescence or apoptosis in response to a G4L.
A fewG4Ls such as RHPS4 (14,15), napthalene diimides
(16), acridine derivatives (6) and EMICORON (17) exhibit
antitumor activity in animal models either alone or in com-
bination with other anticancer agents (for a review: (18)).
Despite a flurry of G4Ls described in the literature recently
(for a recent review: (19)), only a fewG4-related compounds
have been tested in clinical trials, and none have progressed
through the drug-development pipeline. There is, therefore,
an urgent need to identify G4Ls with better drug-like prop-
erties. The 2,4,6-triarylpyridines bind to G4-DNA with fair
to excellent selectivity (20). Among these derivatives, com-
pound 20A (compound #3 in reference (20)) has a good
affinity and selectivity for G4, and the structure of the G4-
ligand complex was recently solved (21). Its ability to inhibit
the proliferation of HeLa cells (20) prompted us to study its
anticancer mechanism of action in vitro and in vivo.
Macroautophagy (often simply referred to autophagy) is
a vesicular mechanism by which cellular components are
transported to the lysosome for degradation and recycling
(22). This process is orchestrated by autophagy-related pro-
teins and is regulated through complex signaling pathways
that converge mostly on the AMPK/MTORC1 axis (22–
24). Autophagy serves as an adaptive mechanism allow-
ing cell viability in response to stress including those to
which cancer cells are exposed (e.g. hypoxia, environmental
changes and DNA damage) (25). Autophagy is also impor-
tant in cell homeostasis as it induces selective degradation of
unwanted mitochondria, aggregated proteins and specific
signaling proteins (26). Autophagy is now considered indis-
pensable for development, cell survival, differentiation and
immune responses. Over the last two decades, it has been
established that autophagy and cancer are interconnected
(27–29). Notably, autophagy is activated in response to a
variety of anticancer agents (30). In most cases, the activa-
tion of autophagy by cancer therapies confers tumor protec-
tion that results in therapy resistance. However, in response
to some anticancer therapies, autophagy induces immuno-
genic and non-immunogenic cell death or growth arrest (30–
33). Upon DNA damage, autophagy modulates the DDR
through regulation of cell-cycle checkpoints, induction of
apoptotic cell death and the activation of the DNA repair
machinery (34,35).
Few studies have examined the regulation and the role of
autophagy in response to G4 ligands (13,36,37). The inter-
relationships between autophagy, cell growth arrest and cell
death induced by these ligands are largely unexplored, how-
ever. Using a variety of approaches, we investigated the
molecular connections between DDR and autophagy and
explored how these regulatory mechanisms influence cell
fate choice between senescence and apoptosis in response
to the G4 ligand 20A.
MATERIALS AND METHODS
Reagents
ATM inhibitor KU-55933 (#SML1109), Hoechst
33258 (#14530), E64d (#516485), bafilomycin
A1 (#B1793), 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide, MTT (#M2128), blasticidine
(#3513-03-9), Fluoromount (#F4680), puromycin (#58-
58-2), Quinoline-Val-Asp-Difluorophenoxymethyl Ketone,
QVD-OPH (# SML0063) and doxycycline (Dox) (#D9891)
were purchased from Sigma-Aldrich. Pepstatin A methyl
ester (#516485) and epoxomycin (# 134381-21-8) were ob-
tained from Calbiochem. Tetramethyl rhodamine methyl
ester perchlorate dye (#T-668) and carboxyfluorescein
succinimidyl ester (CFSE) (#C34554) were purchased from
Molecular Probes. LY2603618 (#S2626) was purchased
from Selleckchem. 20A was synthesized as previously de-
scribed (compound #3 in (20)). Sentragor (#AR8850020)
for antibody-enhanced detection of senescence cells was
provided by Arriani Pharmaceuticals.
Antibodies
Antibodies against the following proteins were used:
phospho-ATM (Ser 1981) (#5883), ataxiatelangiecta-
sia mutated, ATM (#2873), phospho-AMPK (Thr172)
(#2535), AMPK1 (#2795), phospho-AMPK substrates
(#5759), ATG7 (#8558), cleaved caspase 3 (#9664),
phospho-CHK1 (Ser 345, 133D3) (#2348), CHK1
(2G1D5) (#2360), phospho-CHK2 (Thr 68) (#2197),
CHK2 (#2662), p21 Waf1/CIP1 (12D1) (#2947), p27
Kip 1 (D69C12) XP (#3686), phospho 4EBP1 (Thr
37/46) (#9459), 4EBP1 (#9452), phospho-p70S6 ki-
nase (Thr389) (#9205), p70S6 kinase (#9202), H2AX
(Ser139) (#9718), H2A.X (D17A3) XP (#7631) and
phospho-MTOR (Ser2448) (#2971) all from Cell Signal-
ing Technology); Ki67 (30-9) (#790-4286) from Roche;
PARP1 (C-2-10) (#BML-SA249-0050) from Enzo Life
Sciences; p62 (#610832) from BD Biosciences; ATG5
(#0262-100/ATG5-7C6) from Nanotools; ACTIN 
(#NB600-501) from Novus Biologicals; LC3 (#M152-
3) from MBL; phospho-p62 (Ser403) (#MABC186)
from Merck Millipore; p16 (#805-4713) from Ventana;
horseradish peroxidase-conjugated anti-rabbit (#111-
035-003) and horseradish peroxidase (HRP)-conjugated
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anti-mouse (#115-035-174) from Jackson ImmunoRe-
search; and anti-mouse (#A11001) and anti-rabbit Alexa
Fluor 488 (#A11008) from Invitrogen.
Cell culture
The human cervical cancer cell line HeLa and the hu-
man lung carcinoma A549 cell line were purchased from
the American Type Culture Collection. HeLa and A549
cells were grown in RPMI 1640 and Dulbecco’s modi-
fied Eagle’s medium (DMEM) culture media, respectively,
supplemented with 10% fetal bovine serum, 100 units/ml
penicillin, 100 g/ml streptomycin and 2 mM glutamine
(Gibco-Life Technologies). Saos-2 cells were grown in
DMEM supplemented with 10% fetal bovine serum, 100
units/ml penicillin and 100 g/ml streptomycin (Gibco-
Life Technologies). p53 expression was induced in Saos-
2 cells following addition of 0.5 g/ml Dox to the cell
medium. After 6 hours, the medium was replaced with
medium without Dox and then supplemented with the ap-
propriate treatment. All cell lines used in this studywere cul-
tivated at 37◦C in a humidified atmosphere with 5% CO2.
Cell viability assay
Cell viability was evaluated using theMTT assay. Cells were
seeded in a 96-well plate (4 × 103 cells/well). After 24 h of
drug treatment, MTT was added to each well to a final con-
centration of 0.5 mg/ml, followed by incubation at 37◦C for
3 h. Themediumwas then removed, and 100l of dimethyl-
sufoxide (DMSO) was added per well. The absorbance in
eachwell wasmeasured at 570 nmand 630 nmusing aFlexs-
tation 3 microplate reader (Molecular Devices). To deter-
mine the IC50 of 20A, a non-linear regression curve was fit
using GraphPad Prism software.
Cell division assay
HeLa cells were labeled with 1 M CFSE on day zero and
then subjected to flow cytometry analysis to monitor CFSE
dilution, which occurs with cell division on indicated days.
The median fluorescence intensity (MFI) was scored every
day, and the results are expressed as the mean percentage of
MFI normalized to that obtained from day zero.
Apoptosis analysis
Apoptosis was determined by measuring the mitochondrial
transmembrane potential (m) using tetramethyl rho-
daminemethyl ester perchlorate dye as previously described
(38). Apoptosis was also evaluated bywestern blotting anal-
yses of cleaved forms of either PARP1 or caspase 3.
Senescence assay
Cells were stained for senescence-associated -
galactosidase activity using a kit from Cell Signaling
Technology (#9860) as per the manufacturer’s instructions.
Ten images were acquired on a CKX41 Olympus micro-
scope 20× objective for each experimental condition. The
percentages of -galactosidase-positive cells were scored
using Image J software. Results are given as means ± S.D.
of four independent experiments. The in vivo senescence
assay was performed in tumor sections using SenTraGor™,
a Sudan Black B analog conjugated with biotin, which
reacts with lipofuscin granules that have been shown to
accumulate during the senescence process (39).
Meta-TIF assay
The meta-TIF assay for detection of telomere-induced foci
(TIF) in metaphase spreads was performed as described
previously (40). See also the experimental procedure in the
Supplementary Data (part I).
Protein expression analysis
Cell extracts were prepared in 10 mM Tris, pH 7.4, 1%
sodium dodecyl sulphate, 1 mM sodium vanadate, 2 mM
phenylmethylsulfonylfluoride (Sigma-Aldrich), 1% Pro-
tease Inhibitor Cocktail (Sigma-Aldrich) and 1% Halt
Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific).
Extracts were treated with benzonase endonuclease (Merck
Millipore) and then heated for 5 min at 95◦C. For west-
ern blotting, aliquots of cellular extracts (20–50 g) were
subjected to sodium dodecyl sulphate-polyacrylamide gel
electrophoresis using a Tris/glycine buffer system based on
the method of Laemmli as previously described (41). Af-
ter electrophoresis, proteins were transferred to a nitrocel-
lulose membrane (GE Healthcare Life Sciences). The blots
were then probed with primary antibodies using the manu-
facturer’s protocol and then incubated with the appropriate
HRP-conjugated secondary antibody. Staining for ACTIN
 and staining with Ponceau Red were scored to evaluate
the protein loading levels of the samples. Immunostained
proteins were visualized on a chemiluminescence detector
equipped with a camera (FUSION FX7, Fisher Bioblock
Scientific) using the enhanced chemiluminescence detection
system. The densitometry quantification was performed us-
ing the ImageJ software. For all of the immunoblots, repre-
sentative images of at least two experiments are shown.
Label-free quantitative proteomics
The proteomic experiments and analyses were performed
by the Proteomics Core Facility at the University of Bor-
deaux (https://proteome.cgfb.u-bordeaux.fr/en). The steps
of sample preparation, protein digestion and nano-liquid
chromatography-tandem mass spectrometry analysis were
performed as previously described (42). For protein iden-
tification, Sequest HT and Mascot 2.4 algorithms through
Proteome Discoverer 1.4 Software (Thermo Fisher Scien-
tific) were used for protein identification in batch mode
by searching against a Homo sapiens database (68 978 en-
tries, Reference Proteome Set, release 2013 12 fromUniProt
website). Two missed enzyme cleavages were allowed. Mass
tolerances in MS and MS/MS were set to 10 ppm and
0.02 Da. Oxidation of methionine, acetylation of lysine and
deamidation of asparagine and glutamine were searched as
dynamic modifications. Carbamidomethylation on cysteine
was searched as static modification. Peptide validation was
performed using Percolator algorithm (43), and only ‘high
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confidence’ peptides were retained corresponding to a 1%
false discovery rate (FDR) at the peptide level. Feature de-
tection, alignment and quantification were performed with
Progenesis QI with parameters as previously described (44).
Only non-conflicting features and unique peptides (FDR
<1%) were considered for calculation of quantification at
the protein level. A minimum of two peptides matched to a
protein was used as the criteria for identification as a differ-
entially expressed protein.
RNA extraction and microarray experiments
Total RNAs were extracted from cells with Trizol reagent
(Life Technologies) and purified with the RNeasy Min
EluteCleanupKit (Qiagen) according to themanufacturer’s
procedures. RNA was quantified using a Nanodrop 1000
spectrophotometer (Thermo Scientific), and RNA quality
was checked on an Agilent 2100 bioanalyzer (Agilent Tech-
nologies). Microarray experiments were performed using
Agilent-014 850 Whole Human Genome Microarray 4 ×
44K G4112F array according to the manufacturer’s recom-
mended protocol.
Transcriptome and proteome analyses
The experimental designs and data filtering results are sum-
marized in Supplementary Figure S4A. Briefly, the variabil-
ity between replicates for each gene was computed as the
standard deviation divided by the mean. Thresholds of 0.5
and 0.1 were set according to distributions in proteomic
and transcriptomic analyses, respectively. Using a princi-
pal component analysis (Supplementary Figure S4B and
C), we identified samples not clustered properly with their
respective replicates and discarded them from subsequent
analysis. We first monitored changes in gene expression in-
duced by 20A by comparison of transcriptomes of untreated
and 20A-treated HeLa cells using Agilent microarrays. We
found a good correlation between log fold changes at 6 h
(x-axis) and 16 h (y-axis) in transcriptomic (R = 0.68) and
proteomic data (R= 0.81) (Supplementary Figure S5A and
B). The number of up-regulated genes was higher than the
number of down-regulated genes (595 versus 95 after 6 h of
treatment; 317 versus 184 after 16 h) as evidenced by the
volcano plots (Supplementary Figure S5C).
Differential expression. Statistical analyses were per-
formed in R version 3.3.1. We processed the proteomic data
using DESeq2 package version 1.14.1 with default param-
eters (45). Proteomic data have the same biases as gene ex-
pression data in that the high abundance of some proteins
and lengths of the proteins are known to distort the signal.
We used the normalized abundance per gene as counts. We
processed the transcriptomic data using limma package ver-
sion 3.30.13 following usual preprocessing steps (46): agi-
lent files were loaded and processed, background correction
was applied, control probeswere removed, quantile normal-
ization was applied, average signal per gene were computed
and results were annotated using R package biomaRt ver-
sion 2.30.0 (47) with Ensembl release 87. We used the data
from6-h control samples for comparisons to data fromboth
6 and 16 h 20A-treated samples and modeled gene expres-
sion with linear model functions from the limma package.
The full transcriptome/proteome analysis is provided as a
separate xls file.
Functional enrichment and KEGG pathways. Functional
enrichment was computed using command line version of
GSEA software and the Hallmark datasets (48–50). We
then deepened the analyses using the KEGG datasets (51).
We put a maximum threshold of 0.01 on the FDR. We next
used the pathview R package version 1.14.0 to visualize the
behavior of genes and proteins at 6 and 16 h in relevant
KEGG pathways (52).
G4 enrichment. G4 regions were predicted by analysis of
the human genome version hg38 using G4Hunter with de-
fault parameters (threshold = 1.52; window = 25) (2). A
threshold of 1.2 on the score was used. Statistical enrich-
ment of G4 complexes around the transcription start sites
and transcription terminal sites of differentially expressed
transcripts (FDR <0.01 and the absolute log fold change
>1) was computed by a binomial test. The expected fre-
quencies were estimated from the observed frequency in all
genes present in the transcriptomic analysis. We used a slid-
ing window of 100 bp with 50-bp step from the transcrip-
tion start site or the termination site to 1 kb upstream (pro-
moter, 3′UTR) and downstream (5′UTR, downstream of
the gene).
Immunofluorescence analyses
Cells were fixed at room temperature with 4% (v/v)
paraformaldehyde for 10 min and then permeabilized with
50 g/ml digitonin before incubation with the LC3 anti-
body. Cells were then stained with appropriate Alexa Fluor-
conjugated secondary antibody.Nuclei were counterstained
for 10 min with Hoechst 33258. The fluorescence of cells
was examined using a Zeiss LSM510 META confocal mi-
croscope (Zeiss) with an ApoPLAN ×63 objective. Identi-
cal exposures were used for each channel throughout indi-
vidual experiments.
Lentiviral vector production and cell transduction
The CRISPR-Cas9 lentivirus system was used to gen-
erate autophagy-deficient HeLa cell lines. The pLenti
CRISPR (pXPR) vector expressing Cas9 and the single
guide (sg)RNAs that target ATG5 or ATG7 or non-specific
sgRNA control were constructed and validated in the labo-
ratory of Prof. Kevin M Ryan (Beatson Institute of Health,
University of Glasgow). The lentiviral tdTomato-expressing
vector (a generous gift from Prof. Richard Iggo, Univer-
sity of Bordeaux) was used to monitor tumor growth in the
in vivo experiments. For cell transduction experiments, cells
were plated in a 6-well plate (105 cells/well) 24h prior to in-
fection with either the tdTomato vector or the CRISPR ex-
pressing vectors (sgControl, sgATG5 and sgATG7) for 24 h.
The titer of each lentiviral batch was determined on HeLa
cells. At 24h post infection, cells expressing the vector td-
Tomato or the CRISPR-Cas9 vectors were selected in cul-
ture media supplemented with either 10 g/ml blasticidine
for 5 days or 2 g/ml puromycin for 72 h, respectively.
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Transient transfection with small interfering RNA
A non-specific control small interfering RNA (siRNA)
(Sense: 5′-CUUACGCUGAGUACUUCGAtt-3′)
and a specific siRNA that targets ATM (sense 5′-
AACATACTACTCAAAGACAtt-3′) were previously
validated (53) and were synthesized by Eurogentec. Cells
were plated in a 12-well plate (4 × 104 cells/well) and were
transiently transfected with 100 nM siRNA using Oligo-
fectamine (ThermoFisher) following the manufacturer’s
instructions. After 24 h, cells were treated with drugs at the
indicated concentrations.
Autophagy assay
Autophagy was evaluated by (i) western blotting analysis
of the abundance of the autophagosome marker LC3 in the
presence and absence of the lysosomal inhibitors, (ii) a fluo-
rescence microscopy counting of cells with LC3 puncta and
(iii) cellular ultrastructure analysis of the presence of au-
tophagosome by transmission electron microscopy (TEM).
Briefly, cell pellets were fixed in a 1.6% glutaraldehyde solu-
tion in 0.1 M cacodylate buffer at room temperature and
stored overnight at 4◦C. After three rinses in 0.1 M ca-
codylate buffer (15 min each), pellets were post-fixed in a
1% osmium tetroxide and 1% potassium ferrocyanide so-
lution in 0.1 M cacodylate buffer for 1 h at room tempera-
ture to enhance the staining of cytoplasmicmembranes. The
cells were subsequently dehydrated in a series of acetone
baths (90%, 100% three times, 15 min each) and progres-
sively embedded in Epon 812 (Fluka) resin (acetone/resin
1:1, 100% resin two times, 2 h for each bath). Resin blocks
were hardened in a 60◦C oven for 2 days. Ultrathin sections
(70 nm) were obtained with a Reichert Ultracut S ultrami-
crotome equipped with a Drukker International diamond
knife and collected on 200-mesh copper grids. The sections
were stained with lead citrate and uranyl acetate. TEM ob-
servations were performed with a JEOL JEM-1400 trans-
mission electron microscope equipped with aMorada cam-
era at a 100 kV acceleration voltage.
Xenograft tumor formation and immunohistochemistry
The study was performed in accordance with Euro-
pean Community Standards of Care (animal house au-
thorization number B33063916). Approval for the ani-
mal experiments was obtained by the Comite´ d’Ethique
pour l’Experimentation Animale (CEEA50), Bordeaux
(project number APAFIS = 9321-2017031417171591). For
xenograft tumor formation, 2 × 106 tdTomato-expressing
HeLa cells were suspended in 100 l of RPMI medium
and subcutaneously injected in the right flank of 8-week-old
male NSG mice (NOD-scid IL2RG−/−, Jackson Labora-
tory) (54). When the tdTomato fluorescence average within
the tumors reached 6 × 109, the tumor-bearing mice were
randomly assigned to three groups (10 mice/group) and
received peritumoral injections of 100 l of vehicle (15%
DMSO) or 20A at either 10 or 20 mg/kg per mouse 5
days a week for a total of 12 days. Weights were scored
weekly. The tdTomato fluorescence within the tumor was
measured twice aweek using a PhotonIMAGER (Biospace)
from day 35 after cell injection. Results are expressed in
photon intensity (photon/second/steradian) and normal-
ized for each group to the values of fluorescence obtained
at day 35 after cell injection. At the day of the sacrifice, tu-
mor blocks were fixed in 4% formol and paraffin embedded
for hematoxylin-eosin-saffron staining and immunohisto-
chemical labeling of cell proliferationmarker Ki67, apopto-
sis marker cleaved-caspase 3 and Sudan Black B for detec-
tion of lipofuscin-containing senescent cells following the
respective manufacturer’s instruction. High-quality images
were made with slide scanner Nanozoomer (Hamamatsu)
in the Bordeaux Imaging Center. Tumor morphology and
immunohistochemical staining were analyzed by a pathol-
ogist.
Statistical analysis
Data are presented as means and error bars as standard de-
viations (SD) of at least three independent experiments un-
less otherwise stated. Comparisons of the different groups
were made with either Mann–Whitney unpaired test or un-
paired t test. For the in vivo experiments, the results are ex-
pressed as means, error bars as standard errors of the mean
(SEM) and comparisons of the different groups were with
Mann–Whitney unpaired test. Values of *P < 0.05, **P <
0.01, ***P< 0.001, ****P< 0.0001 were considered statis-
tically significant. The software used was GraphPad Prism.
RESULTS
Antiproliferative effects of 20A result from induction of senes-
cence and apoptosis
20A inhibits the viability of HeLa cells in a dose-dependent
manner with a halfmaximal inhibitory concentration (IC50)
of 6.5 M after 24 h of treatment (Figure 1A). 20A treat-
ment compromises cell division as demonstrated by the de-
lay of CFSE dye dilution, which occurs due to cell division
(55), as compared to untreated cells (Figure 1B).
To determine if p53 status influences the loss in cell viabil-
ity caused by 20A treatment, we used the Saos-2 osteosar-
coma cell line. These cells display no endogenous p53 ex-
pression but contain a Dox-inducible p53 transgene (56).
As illustrated in Figure 1C, both Saos-2 cells that do not ex-
press p53 (-Dox) and Saos-2 cells expressing the p53 trans-
gene (+Dox) were equally sensitive to 20A as shown by
nearly superimposable survival curves (IC50 values are 3.3
and 3.2 M, respectively). This experiment demonstrated
that the antiproliferative effect of 20A is independent of the
presence or absence of p53 in cells.
To explore the mechanisms responsible for the antiprolif-
erative action of 20A, we further examined senescence and
apoptotic cell death, two well-defined processes involved
in cell growth arrest and programmed cell death, respec-
tively. Senescence was evaluated by using Senescence As-
sociated -Galactosidase assay. 20A treatment resulted in
a dose-dependent increase in the percentage of cells stained
for -galactosidase (Figure 1D), suggesting that 20A causes
senescence. We also evaluated the levels of two senescence
markers, p21 and p27. As shown in Figure 1E, 20A treat-
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/47/6/2739/5316735 by U
niversity of G
lasgow
 user on 10 M
arch 2020
2744 Nucleic Acids Research, 2019, Vol. 47, No. 6
Figure 1. 20A treatment results in cancer cell growth arrest through the induction of senescence and apoptosis. (A) Viability of HeLa cells after a 24-h
exposure to 20A at concentrations ranging from 1 to 10 M. Plotted are means± S.D. of three independent experiments, each performed in quadruplicate.
(B) HeLa cells were labeled with 1 M CFSE (day 0) and then treated with 6 M 20A. Flow cytometry analysis of the CFSE fluorescence intensity was
monitored on indicated days. Left, representative flow cytometry traces in which the red histogram corresponds to the day of cell staining (day 0). Control
cells were mock treated. Right, results expressed as MFI normalized to that obtained from day zero. Plotted are means ± S.D. of six values obtained
from two independent experiments, each performed in triplicate. **P < 0.01 using Mann–Whitney test. (C) Saos-2 cells were grown in either the presence
or absence of 0.5 g/ml Dox for 6 h and then treated for 24 h with the indicated concentration of 20A. Plotted are means ± S.D. of three independent
experiments, each performed in quadruplicate. Inset represents western blot analysis of p53 expression levels in Saos-2 cells grown in the presence or
absence of 0.5 g/ml Dox for 6 h; ACTIN was detected as a loading control. (D) HeLa cells were treated with 6 M 20A for the indicated time and then
stained for -galactosidase activity to detect senescence. Left, representative images of cells stained for -galactosidase (arrowheads indicate senescent
cells; scale bar = 50 m). Total cell number and total number of -galactosidase-positive cells were scored to determine the fraction of senescent cells.
Data are means ± S.D. of four independent experiments; at least 100 cells from 10 randomly chosen fields were counted in each experiment. *P < 0.05
using Mann–Whitney test. (E) Representative immunoblot analysis of p21, p27 and ACTIN levels in HeLa cells treated with 6 M 20A for the indicated
time. (F) Apoptotic cell death evaluated after treatment of HeLa cells with the indicated concentration of 20A for 24 h. Left, percentage of cells that have
lost mitochondrial transmembrane potential (m) plotted versus 20A concentration. Results are means ± S.D. of triplicate data obtained from one
experiment. Right, immunoblot analysis of cleaved forms of caspase 3 and PARP1 in cells treated with the indicated concentrations of 20A; ACTIN was
detected as a loading control.
ment elicited a significant time-dependent up-regulation of
both p21 and p27 proteins in HeLa cells.
Treatment of cells with 20A also induced a dose-
dependent activation of apoptosis as evidenced by loss of
the mitochondrial transmembrane potential as well as the
appearance of cleaved forms of caspase 3 and PARP1 (Fig-
ure 1F). Accordingly, in cells treated with QVD-OPh, an
inhibitor of caspases, cell death induced by 20A was re-
duced (Supplementary Figure S1A). Moreover, senescence
and apoptosis were observed after 48 and 72 h (Supplemen-
tary Figure S1B and C) suggesting that the cells do not es-
cape senescence over time. 20A treatment also led to senes-
cence and apoptosis in other cancer cells such as lung carci-
noma A549 cells (which express p53) (Supplementary Fig-
ure S2A) and Saos-2 cells expressing or not p53 (Supple-
mentary Figure S2B). Together, these results demonstrate
that 20A treatment causes a loss of cell viability by induc-
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ing senescence and caspase-driven apoptotic cell death in a
p53-independent manner.
20A has antitumor effects in vivo
The significant antiproliferative effect of 20A in HeLa cells
prompted us to determine whether this compound had an-
titumor properties in a mouse model of cancer. To this end,
HeLa cells that stably express tdTomato, which encodes a
red fluorescent protein, were subcutaneously injected into
the dorsal flank of NOD scid  mice. Tumor growth was
monitored by live imaging of the red fluorescence within
the xenografts. When the tumors reached a sufficient vol-
ume, peritumoral daily injections of either DMSO (vehicle
control) or 10 or 20 mg/kg 20A were given over a period of
12 days. Tumor growth was significantly reduced after 12-
day treatment with both doses of 20A as evidenced in live
animal images (Figure 2A, 3 representative animals out of
10 mice are presented for each group in Figure 2B). Dur-
ing the period of the treatment, the average weight of the
mice from the two 20A-treated groups did not differ signif-
icantly from that of the control group, suggesting that 20A
had low toxicity in this in vivomodel (Supplementary Figure
S3A). At the end of the treatment, the tumor characteristics
were analyzed. Hematoxylin, eosin and saffron staining of
DMSO-treated xenografts revealed the presence of marked
atypia andmitotic activity with scattered inflammatory cells
in HeLa tumor xenografts (Figure 2C, left panel). In con-
trast, 20A-treated tumor samples had a low density of ma-
lignant cells and areas of necrosis, fibrosis and adiponecro-
sis were observed in HeLa xenografts from mice treated
with 20 mg/kg 20A (Figure 2C, right panel) and 10 mg/kg
20A (Supplementary Figure S3B, right panel). Immunohis-
tochemistry labeling for the DNA replication marker Ki67
revealed that the percentage of proliferating cells in 20A-
treated tumor xenografts was reduced compared toDMSO-
treated tumors (Figure 2C). Tumor xenografts treated with
10 mg/kg 20A manifested also some features of apopto-
sis or senescence as evidenced by the cleaved forms of cas-
pase 3 and Sudan Black B labeling, respectively (Supple-
mentary Figure S3B). Taken together, these in vivo data con-
firm those obtained in vitro and indicate that 20A treatment
promotes an arrest of tumor growth along with induction
of apoptosis and senescence.
Molecular pathways altered by 20A treatment
To identify the biological pathways and signaling net-
works affected by 20A, we investigated its global effects on
gene transcription and protein expression levels in HeLa
cells (Supplementary Figures S4 and S5). 20A induces
both up- and down-regulation of genes (595 versus 95
after 6 h of treatment, Supplementary Figure S5C; 317
versus 184 after 16 h, as shown in Figure 3A). An en-
richment analysis performed using the Broad Gene Set
Enrichment Analysis (GSEA) and the Molecular Signa-
tures Database (MSigDB) (50,52) revealed that 20A in-
duces a significant enrichment in a number of biological
pathways including pathways involved in DNA damage
(p53 PATHWAY), apoptosis (APOPTOSIS) and lysosomal
function (MTORC1 SIGNALING, PROTEIN SECRE-
TION) (Table 1; a complete list of genes up- or down-
regulated is provided as a Supplementary File 1 in excel for-
mat). Using the KEGG database, we found a significant en-
richment of biological pathways related to the DNA dam-
age (MISMATCH REPAIR, up-regulated) and cell growth
(CELL CYCLE, down-regulated) as well as pathways re-
lated to autophagy (REGULATION OF AUTOPHAGY
and LYSOSOME) (Supplementary Table S1). The dia-
gram in Figure 3B recapitulates the transcriptome analy-
sis of three interconnected KEGG signaling pathways (p53,
MTORC1 and AUTOPHAGY) that are significantly en-
riched in response to 20A treatment (Supplementary Ta-
ble S2 and Supplementary Figure S6). This figure reveals
that 20A elicits (i) activation of DDR as evidenced by up-
regulation of Chk1 and Chk2, which encode downstream
effectors of ATR and ATM, respectively; (ii) up-regulation
of two senescence effectors, p21 and pRb, and the down-
regulation of the Rb target, E2F; (iii) the modulation of
apoptosis as evidenced by up-regulation of Cytc and Casp3
and down-regulation of both Bax and Casp9; and (iv) a
significant down-regulation of expression of genes encod-
ing elements of the MTORC1 complex associated with in-
creased expression of a large panel of autophagic and lyso-
somal genes (e.g. Beclin1, VPS34, ATG5, ATG12, ATG3,
LC3, p62, OPTN, NBR1, Lamp and CTS) (23,57,58).
The proteome data were also analyzed with the GSEA,
MSigDB andKEGGdatabases (50,52), which revealed that
several Hallmark sets were affected by 20A treatment (Table
1 and Supplementary Table S1). These sets included those
found in the transcriptome experiments (i.e. apoptosis, the
p53 pathway and protein secretion).
To determine whether a causal link existed between
changes in transcript or protein levels and the presence of
G4 sequences within key regulatory elements of the cor-
responding genes, we performed a bioinformatics analysis
using G4-Hunter (2). We analyzed for the enrichment of
sequences with G4-forming potential around transcription
start and end sites in up- and down-regulated transcripts.
The analysis showed an enrichment of sequences with G4-
forming potential directly upstream (50–150 bp) of tran-
scription termination sites of genes down-regulated after
both 6 and 16 h of treatment with 20A (Supplementary Fig-
ure S7A). This observation is in line with previous results
showing that G4 ligands may not only regulate transcrip-
tion via the regulation of promoter activity but may also in-
fluence later transcriptional events as well as the maturation
of specific messenger RNAs (10).
We then performed an analysis of G4 density in gene
bodies of up-regulated, and down-regulated transcripts and
transcripts unchanged by 20A treatment. Interestingly, and
in agreement with its proposed mode of action, down-
regulated gene bodies carry higher G4 densities (expressed
as number of G4 sites per kb) than unchanged genes and
up-regulated genes (Figure 3C for analysis after 16 h; 6-h
data shown in Supplementary Figure S7B). This observa-
tion, which is significant both after 6 and 16 h, suggests that
a high density of G4 structures bound to 20A block tran-
scription, whereas the quasi-absence of G4-forming motifs
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Figure 2. 20A treatment compromises tumor growth inmice bearingHeLa xenografts. (A) The tdTomato fluorescence within tumors was recorded inHeLa
xenografts in mice during the treatment period with DMSO (control) or 10 or 20 mg/kg 20A per injection. Tumor growth is plotted as means ± S.E.M.
of the relative fluorescence intensity within the xenografts scored on indicated days following tumor implantation from 10 mice per group. P **<0.01;
***<0.001; ****<0.0001 with Mann–Whitney test compared to DMSO-treated group. (B) For each treatment group, images of three representative mice
are shown at day 12 after treatment initiation. The fluorescence intensity is presented as a rainbow scale with increasing intensity from blue to red. The
green circles represent areas used to measure total fluorescence intensity. (C) Representative images of hematoxylin-eosin-saffron stained DMSO-treated
and 20 mg/kg 20A-treated tumor sections performed at the end of the treatment period. Arrow indicates tumor cells with necrosis and asterisk shows
fibrosis and adiponecrosis. Immunohistochemistry (IHC) analyses for Ki67 expression were also performed on the paraffin-embedded sections of tumor
tissues.
in the gene bodies of up-regulated genes protects these genes
from down-regulation by 20A.
20A promotes a global DNA damage response but not telom-
eric damage
As several G4Ls have been shown to induce telomeric DNA
damage, we investigated whether this is the case for 20A
using the meta-TIF assay (40). We scored the abundance
of TIF, which correspond to sites of DNA damage (as ev-
idenced by the DNA damage marker H2AX) that co-
localize with telomeres revealed by a telomere-specific pep-
tide nucleic acid probe. As shown in Figure 4A, 20A did not
augment the frequency of TIF in any of the cell lines tested.
This observation, together with the quantitative polymerase
chain reaction (qPCR) assay results (Supplementary Figure
S8), reinforces our conclusion that no important telomere
shortening occurred after 20A treatment.
However, we observed that 20A treated cells elicit in-
creased in the frequencies of metaphase chromosomes en-
tirely covered by H2AX (which we call here global DDR)
as compared to untreated cells, which was statistically sig-
nificant for A549 and Saos-2 cells (Figure 4B). These re-
sults indicate that 20A induces DNA damage without en-
richment at chromosomal ends. A time-course experiment
showed the H2AX levels increased as early as 30 min fol-
lowing 20A treatment and remained elevated after 48 h of
treatment. (Figure 4C; the quantification of four indepen-
dent experiments over a 4-h time course is presented in Sup-
plementary Figure S9).
This global DDR prompted us to examine whether the
effects of classical DNA damaging agents correlate with
the transcription profile of 20A. To test this hypothesis,
we located publicly available expression data from HeLa
cells treated with X-rays or chemicals. After abstract cu-
ration and dataset exploration, we selected three studies:
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Figure 3. Transcriptome analysis of 20A treated cells. (A) Global changes in gene expression in 20A treated cells. limma differential expression results are
plotted with the x-axis showing the log fold changes between 6 M 20A treatment versus control cells (after 16 h, Figure 3A) or 6 h, Figure S2C) and the
y-axis showing the significance of the statistical tests (p corrected for multi-testing minus log transformed). Green and red dots highlight significantly down-
and up-regulated genes (absolute log fold change above 1 and significance above 2; P < 0.01). Results related to the proteomics analysis are presented in
Figure S2A and S2B and Table S1. (B) Results obtained on three interconnected KEGG signaling pathways that are significantly enriched in response to
20A treatment (p53, MTORC1 and autophagy; each pathway is individually shown in Figure S6). For each gene product, the value of log fold change at 6
h (in the left part of the box) and log fold change at 16 h (in the right part of the box) are presented and denoted with the color code presented on the top of
the figure. Log fold change values between −0.3 and 0.3 are colored in gray, those between 0.3 and 0.9 are in light orange, above 0.9 are in orange, between
-0.3 and -0.9 are in light blue and those below -0.9 are in dark blue. Solid lines represent direct regulation, dotted lines represent indirect regulation and
‘+p’ indicates regulation by phosphorylation. (C) G4 density in gene bodies for genes down-regulated by 20A, not significantly affected (‘stable’) by 6 M
20A, or up-regulated after 16 h of treatment with 20A. Results obtained after 6 h are presented in Figure S7B. ****p< 0.0001 versus genes down-regulated.
GSE19526 (X-ray irradiation); GSE95227 (UV-C irradia-
tion) and GSE72905 (ruthenium complex treatment). We
computed expression changes between treated (X-ray, neu-
tron, RuT7) and control HeLa cells and observed no corre-
lation between the effects of these treatments and 20A ef-
fects. These results are presented in detail in Supplemen-
tary Information Part II. These analyses clearly demon-
strate that the observed transcriptional alterations induced
by 20A do not correspond to a classical general response to
DNA damage.
To gain further insight into the regulation of the DDR
pathway by 20A, we explored the activation of the ATM
and ATR, two key DDR sensors (59), after 20A treatment.
As shown in Figure 4D, cells subjected to 20A treatment
displayed a rapid and robust stimulation of ATM and its
downstream target CHK2 (as indicated by increased phos-
phorylation on Ser 1981 and Thr 68, respectively) along
with a rapid activation of the downstream target of ATR,
CHK1 (as indicated by its increased phosphorylation Ser
345). These results suggest that both ATM and ATR path-
ways are activated in response to 20A (Figure 4D).
ATMactivation drives cells to senescence to prevent cell death
induced by 20A
To evaluate the role of ATM in senescence and apoptosis
induced by 20A, we used siRNAs to silence expression of
ATM. As shown in Figure 5A, loss of ATM significantly
reduced senescence induced by 20A, irrespective of the pres-
ence or absence of p53 protein (Figure 5B).Moreover,ATM
silencing markedly enhanced cell killing induced by 20A as
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Table 1. Hallmark gene sets significantly enriched (False discovery rate (FDR) q-value <0.05) after either 6 or 16 h of treatment with 6 M 20A in
transcriptomic or the proteomic data
20A treatment (6 h) 20A treatment (16 h)
HALLMARK NES FDR q-val HALLMARK NES FDR q-val
Transcriptomics
MYC TARGETS V1 2.6544 0 KRAS SIGNALING DN −2.1145 0
MTORC1 SIGNALING 2.6135 0 CHOLESTEROL HOMEOSTASIS 2.6057 0
PROTEIN SECRETION 2.4228 0 MTORC1 SIGNALING 2.4009 0
CHOLESTEROL HOMEOSTASIS 2.4154 0 PROTEIN SECRETION 2.2930 0
ANDROGEN RESPONSE 2.2860 0 FATTY ACID METABOLISM 2.0078 0.00077
TNFA SIGNALING VIA NFKB 2.1413 0 ANDROGEN RESPONSE 1.9120 0.00081
COMPLEMENT 1.9466 0.00032 OXIDATIVE PHOSPHORYLATION 1.7578 0.00396
HYPOXIA 1.8538 0.00125 BILE ACID METABOLISM 1.7664 0.00422
GLYCOLYSIS 1.7893 0.00273 COMPLEMENT 1.6984 0.00605
TGF BETA SIGNALING 1.8056 0.00281 EPITHELIAL MESENCHYMAL TRAN
SITION
−1.7906 0.00639
UNFOLDED PROTEIN RESPONSE 1.7613 0.00297 GLYCOLYSIS 1.6756 0.00713
OXIDATIVE PHOSPHORYLATION 1.7665 0.00305 KRAS SIGNALING UP 1.6542 0.00778
KRAS SIGNALING DN −1.9267 0.00306 HEDGEHOG SIGNALING −1.6975 0.00938
FATTY ACID METABOLISM 1.7571 0.00309 NOTCH SIGNALING −1.7226 0.00940
E2F TARGETS 1.7529 0.00321 PEROXISOME 1.6287 0.01003
HEME METABOLISM 1.6345 0.01004 APICAL JUNCTION −1.6543 0.01156
G2M CHECKPOINT 1.6470 0.01020 HYPOXIA −1.5587 0.01568
IL2 STAT5 SIGNALING 1.6357 0.01067 MYC TARGETS V2 −1.5682 0.01711
UV RESPONSE DN 1.5911 0.01544 HEME METABOLISM 1.5718 0.01773
P53 PATHWAY 1.5564 0.01965 TNFA SIGNALING VIA NFKB −1.4714 0.03031
APOPTOSIS 1.5230 0.02433 MYOGENESIS −1.4066 0.04704
KRAS SIGNALING UP 1.4755 0.04037 XENOBIOTIC METABOLISM 1.4561 0.04803
ESTROGEN RESPONSE LATE 1.4584 0.04467 UNFOLDED PROTEIN RESPONSE 1.4620 0.04819
E2F TARGETS 1.4496 0.04832
Proteomics
OXIDATIVE PHOSPHORYLATION 2.7854 0 OXIDATIVE PHOSPHORYLATION 2.4181 0
INFLAMMATORY RESPONSE 2.0673 0.00315 ESTROGEN RESPONSE EARLY 1.8408 0.00976
ADIPOGENESIS 1.9909 0.00724 ADIPOGENESIS 1.8952 0.00976
COMPLEMENT 1.8457 0.01836 PROTEIN SECRETION 1.8448 0.01083
APOPTOSIS 1.8347 0.01894 APOPTOSIS 1.8111 0.01252
FATTY ACID METABOLISM 1.8702 0.01937 HEME METABOLISM 1.9069 0.01302
EPITHELIAL MESENCHYMAL TR
ANSITION
1.8049 0.02273 IL2 STAT5 SIGNALING 1.6552 0.04166
P53 PATHWAY 1.6676 0.04325
COAGULATION 1.6358 0.04325
ESTROGEN RESPONSE LATE 1.5982 0.04647
EPITHELIAL MESENCHYMAL TRAN
SITION
1.5855 0.04767
NES is the Normalized Enrichment Score given by GSEA, positive values mean an up-regulation of the majority of the genes or proteins involved in the corresponding Hallmark
set, whereas negative values indicate down-regulation of the majority of genes involved in the Hallmark set. The FDR q-value represents the adjusted P-value.
evidenced by loss of mitochondrial transmembrane poten-
tial and the appearance of the cleaved forms of PARP1 and
caspase 3 (Figure 5C), and this response also occurred in
a p53-independent manner (Supplementary Figure S10C).
Similar results were found with KU55933, an ATM kinase
inhibitor (Supplementary Figure S10A and B). Of note,
inhibition of ATM activation compromises 20A-induced
senescence in the presence or absence of the broad caspase
inhibitor QVD-OPh, suggesting that reduced senescence in
absence of ATM is not due to increased apoptosis (Fig-
ure 5D). We also investigated the consequences of ATM
inhibition on the expression of CHK1 and the cyclin de-
pendent kinase inhibitors, p16, p21 and p27. As shown in
Supplementary Figure S10D-E, depletion of ATM follow-
ing 20A treatment reduced CHK1 expression and led to p27
up-regulation, but no significant effect was observed on the
levels of p21 or p16. This suggests that ATM regulates the
stability of both CHK1 and p27 through an as yet unidenti-
fied mechanism. Altogether, these results suggest that ATM
is involved in the establishment of senescence onset to pro-
tect cells against apoptotic cell death induced by 20A.
20A treatment promotes ATM-dependent autophagy activa-
tion and p62 up-regulation
Based on the transcriptome and proteome results, we rea-
soned that the autophagy pathway is triggered by 20A. We
thus explored the activation of theMTORandAMPKaxes,
two pivotal pathways that control autophagy negatively and
positively, respectively (22). As illustrated in Figure 6A and
Supplementary Figure S11A, treatment of HeLa cells with
20A causes MTOR inhibition as evidenced by a decrease in
the phosphorylation of mTOR (on Ser 2488) and of its two
substrates, p70 (on Thr 389) and 4-EBP1 (on Thr 37/46),
as early as 4 h after treatment with 20A was begun. We also
observed a rapid and transient activation of AMPK (as in-
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Figure 4. 20A causes global DNA damage but not telomeric damage. (A) Representative metaphases for HeLa, A549 and Saos2 cells displaying TIFs or
global DDR under two experimental conditions, 24-h treatment with 20A or DMSO. Telomeric DNA (TelC, red), (H2AX, green) and (4′,6-Diamidino-
2-phenylindoledihydrochloride (DAPI), blue). Enlargements of chromosomes with TIFs are shown; scale bar = 10 M. (B) Quantification of metaphases
with at least one TIF or global DDR. Two biological replicates, n = 35–45 metaphases per condition. P-values, statistics of proportions for Global DDR
(black print) and TIFs (gray print), * p value< 0.05 versus untreated cells. (C) HeLa cells were treated with 6 M 20A at time indicated and then subjected
to western blotting analysis for H2AX and total H2AX. (D) Western blotting analysis of the levels of phospho-ATM (Ser 1981), ATM, phospho-CHK1
(Ser 345), CHK1, phospho-CHK2 (Thr68) and CHK2 in HeLa cells following treatment with 6 M 20A for the indicated times.
dicated by an increase of its phosphorylation on Thr 172
and activation of its substrates; Figure 6A and Supplemen-
tary Figure S11B).
To further evaluate the autophagy activity in response to
20A, we determined the abundance of autophagosomes by
performing cellular ultrastructure analysis and by studying
changes in the subcellular localization of the autophago-
some marker LC3. Electron micrographs of HeLa cells re-
vealed that 20A treatment caused accumulation of multi-
membrane vesicles containing electron-densematerials with
features of autophagosomes (Figure 6B). The increase in
abundance of autophagosomes induced by 20A was con-
firmed by immunofluorescence, which showed a significant
increase in LC3 fluorescent dots in 20A-treated cells as com-
pared to untreated cells (Figure 6C, left). Western blot-
ting analysis also showed a time-dependent accumulation
of LC3-II, the form of LC3 protein conjugated to phos-
phatidylethanolamine (Figure 6C, center), a marker of the
autophagosomal membrane that is eventually degraded by
lysosomal proteases (22). Moreover, 20A-induced accumu-
lation of LC3-II was enhanced in the presence of lysosomal
protease inhibitors E64d and pepstatin A, indicating that
the material sequestered within the autophagosomes was
successfully addressed to lysosomes and degraded after 8
h of treatment (Figure 6C, right). We also examined p62, a
protein involved in the selective transport of specific cellu-
lar cargos to autophagosomes (60). As shown in Figure 6D,
20A promoted up-regulation of p62 levels concomitantly
with an increase in the phosphorylation of p62 on serine
403, known to regulate the selective autophagy-mediated
degradation of ubiquitinated proteins. Of note, the expres-
sion levels of p62 were also regulated by the proteasome sys-
tem in these cells since inhibition of proteasome by Epox-
omicin markedly enhanced 20A-induced up-regulation of
p62 protein levels (Supplementary Figure S11C).
As ATM activation has been previously reported to stim-
ulate autophagy following DNA damage (34), we further
explored the influence of this pathway on autophagy induc-
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Figure 5. ATM is activated by 20A to direct cells to senescence instead of apoptosis. In panels A, C and D HeLa cells were transiently transfected with
either ATM siRNA or control siRNA. 20A (6M)was added 24 h later for a period of 24 h. (A) Left: the percent of senescent cells determined as described
in Figure 1D. Data are means± S.D. of four independent experiments. *P< 0.05 usingMann–Whitney test.Upper right, immunoblot analysis of the levels
of ATM protein expression in either the presence or absence of siRNA ATM. Lower right, representative images of cells treated as indicated and stained
for -galactosidase; scale bar = 50 m. (B) Saos-2 cells were grown in either the presence or absence of 0.5 g/ml Dox for 6 h and then treated for 24 h
with 3.5 M 20A. The percentage of senescent cells was determined as described in Figure 1D. Data correspond to the mean ± S.D. of three independent
experiments. (C) Left, apoptotic cell death was scored by measurement of loss of m. The data are presented as means ± S.D. of eight values obtained
from four independent experiments each performed in duplicate. **P < 0.01 using Mann–Whitney test. Right, immunoblot images of the appearance of
the cleaved forms of both caspase 3 and PARP1 are shown. (D) Cells were incubated for 2 h with QVD-OPH (20 M) prior the addition of 6 M 20A for
24 h. The percent of senescent cells determined as described in Figure 1D. Data correspond to the mean ± S.D. of three independent experiments. *ns: not
significant by t-test.
tion by 20A. The effect of the ATM inhibitor KU55933
on the accumulation of the autophagy marker LC3-II in
the presence and absence of two autophagy flux inhibitors
was evaluated. As presented in Figure 6E, the inhibition of
ATM activation by KU55933 prevented 20A-induced ac-
cumulation of LC3-II. This effect was not attributable to
the activation of the autophagy flux, as under this condi-
tion the levels of LC3-II were not enhanced compared to
that of 20A-treated cells when autophagy flux was inhib-
ited by bafilomycin A1 or E64d and pepstatin A. Similar
results were obtained when ATM expression was silenced
by siRNA treatment (Supplementary Figure S11D). Alto-
gether, these data indicate that inhibition ofATMactivation
counteracts 20A-induced autophagy, supporting the idea
that ATM activation is responsible for the activation of au-
tophagy.
Loss of autophagy impairs 20A-induced senescence and
drives cells to apoptosis
In order to evaluate the role of autophagy on global
DDR and cell growth arrest induced by 20A, we used the
CRISPR-Cas9 system to generate two HeLa cell lines with
complete autophagy disruption resulting from deletion of
key autophagy genesATG5 orATG7. ATG5 orATG7 levels
were undetectable in the respective CRISPR-targeted cells
as shown by western blotting (Figure 7A). It is worth not-
ing that disruption of autophagy did not have an effect on
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Figure 6. 20A promotes autophagy induction through a mechanism that involves ATM activation. (A) HeLa cells were treated for the indicated times with
6 M 20A. The activities of the MTORC1 and AMPK pathways were determined by immunoblot analysis using antibodies directed against phospho-
4EBP1 (Thr37/46), 4EBP1, phospho-p70 (Thr 389), p70, phospho-AMPK (Thr 172) and AMPK. (B) Representative electron micrographs of HeLa cells
untreated or treated for 16 h with 6 M 20A. (C) Left, immunofluorescence analysis for the abundance of LC3 puncta (green dots) in HeLa cells after 3 h in
either the absence or presence of 6 M 20A; Hoechst was used to stain nuclei (blue). Representative confocal images are shown; scale bar = 10 m. Center,
immunoblot images of LC3-II levels in HeLa cells treated with 6 M 20A for the indicated times. Right, immunoblot of cells treated with or without E64d
(10 g/ml) plus pepstatin A (2 g/ml) 2 h prior 20A treatment (6 M, 8 h). (D) Immunoblot analysis of phospho-p62 (Ser 403) and p62 levels in HeLa
cells treated with 6 M 20A for the indicated times. (E) Immunoblot analysis of LC3-II levels in HeLa cells incubated with or without 10 M KU55933
for 2 h and then treated with 6 M 20A for 8 h. Where indicated, cells were incubated with 10 g/ml E64d plus 2 g/ml pepstatin A for 2 h prior 20A
treatment. Where noted, bafilomycin A1 (50 nM) was added 3 h before cell lysis.
cell viability under these growth conditions (Supplementary
Figure S11E). As expected, loss of ATG5 or ATG7 abro-
gated the induction of basal levels of autophagy as well
as of 20A-induced autophagy as evidenced by immunoblot
analysis of LC3-II expression levels (Figure 7A). Moreover,
the disruption of autophagy led to accumulation of the au-
tophagy substrate p62 both in control and 20A-treated cells
(Supplementary Figure S11F).
To determine the functional role of autophagy in the an-
tiproliferative effects of 20A, we next examined the effect
of autophagy disruption on senescence and apoptosis trig-
gered by 20A treatment. As shown in Figure 7B, the 20A-
induced senescence phenotype was significantly reduced in
both ATG5- and ATG7-deficient cells as compared to con-
trol cells. Concomitantly, autophagy-deficient cells exhib-
ited higher levels of apoptosis relative to control cells as ev-
idenced by loss of mitochondrial transmembrane potential
and cleavage of both Caspase 3 and PARP1 (Figure 7C).
These results corroborate with those observed when ATM
was inhibited (Figure 5) underscoring the contribution of
autophagy in modulating the balance between senescence
and apoptosis upon 20A treatment.
Because loss of autophagy following DNA damage has
been reported to cause dephosphorylation of CHK1 (at
Ser 345) (61), we explored whether this effect occurs in
response to 20A. As shown in Figure 7D (left, panel),
autophagy-deficient cells exhibited significantly lower levels
of CHK1 phosphorylation in response to 20A as compared
to autophagy-proficient cells. Similarly, loss ofATM led to a
significant decrease of 20A-induced both CHK1 activation
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Figure 7. Autophagy disruption causes a deficiency in CHK1 activation and sensitizes cells to apoptosis induced by 20A. (A) Autophagy disruption inHeLa
cells was validated by immunoblot analysis of ATG5, ATG7, LC3-II in autophagy-proficient (sgControl) and autophagy-deficient (sgATG5 and sgATG7)
cells following treatment with 6 M 20A for 16 h. (B) Left, the percentages of senescent cells were scored by -galactosidase staining as described in Figure
1D in sgControl, sgATG5 and sgATG7 cells after 24h treatment with 6 M 20A. The data are presented as means ± S.D. of four independent experiments.
*P < 0.05 using Mann–Whitney test. Right, representative cell images; scale bar = 50 m. (C) Autophagy-proficient (sgControl) and autophagy-deficient
(sgATG5 and sgATG7) cells were treated with 6 M 20A for 24 h. Left, loss of mitochondrial transmembrane potential was evaluated by flow cytometry.
Data are means ± S.D. of 12 values obtained from four independent experiments each performed in triplicate. **P < 0.01 using Mann–Whitney test.
Right, immunoblot analysis of cleaved forms of caspase 3 and PARP1. (D) Left, immunoblot analysis of phospho-CHK1 (Ser 345) and H2AX (Ser 139)
levels in sgControl, sgATG5 and sgATG7 cells treated with 6 M 20A for the indicated time. Right, loss of mitochondrial transmembrane potential was
evaluated by flow cytometry assay in HeLa cells pretreated for 2 h with the CHK1 inhibitor LY2603618 (0.5 M) prior to treatment with 6 M 20A for
an additional 24 h. The data are presented as means ± S.D. of nine values obtained from three independent experiments each performed in triplicate. **P
< 0.01 using Mann–Whitney test.
and expression arguing for the implication of ATM in the
control of CHK1 stability (Supplementary Figure S10D).
Furthermore, loss of autophagy resulted in an enhanced ac-
cumulation of H2AX at earlier time points after the addi-
tion of 20A, in a time window where apoptotic cell death
was not observed, supporting the idea that the accumula-
tion of H2AX is, at least in part, independent of apop-
totic DNA fragmentation. To determine whether inhibition
of CHK1 activation can phenocopy the loss of autophagy,
we examined the effect of LY2603618, a specific inhibitor
of CHK1 in HeLa cells. Pretreatment of wild-type HeLa
cells with LY2603618 enhanced 20A-induced apoptotic cell
death to the same extent than what was observed in HeLa
cells in which autophagy was disrupted Figure 7D (right,
panel). We thus speculate that CHK1 is one of the regula-
tors of autophagy-mediated DDR and cell survival follow-
ing 20A treatment.
DISCUSSION
Given that the outcome of cancer therapy relies on the can-
cer cell fate––survival, senescence or death––the identifica-
tion of regulatory mechanisms that impact this fate is re-
quired for optimization of the efficacy of cancer treatment
(33,62). The triarylpyridine family of G4 ligands represents
a novel class of DNA ligands that are potential anticancer
agents (21). In the present study, we provide evidence that
20A, a representative compound of this family of G4 lig-
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ands, inhibits cancer cell growth both in vitro and in vivo.We
show that this compound induces senescence and apopto-
sis in a p53-independentmanner. Notably, we demonstrated
that the activation of the ATM/autophagy pathway by 20A
operates as a linchpin between senescence and apoptosis.
To our knowledge, this is the first demonstration that the
ATM/autophagy axis is involved in the cell fate choice be-
tween senescence and apoptosis in cancer cells treated with
a G4 ligand.
The ability of G4 ligands to promote senescence was pre-
viously attributed to stabilization of telomeric G4 struc-
tures, resulting in telomerase inhibition, slowed telomere at-
trition and eventually telomere uncapping (5,12). Replica-
tive senescence is triggered by telomere shortening and ap-
pears after several weeks of treatment with G4 ligands at
sub-lethal doses (5,14). However, increasing evidence indi-
cates that non-telomeric sites also play essential roles in the
biological effects of G4 ligands (7–10). We observed no in-
crease in telomeric damage upon treatment of HeLa cells
with 20A (Figure 4A andB), arguing against preferential ac-
tion of this compound at chromosomal ends. We therefore
assume that 20A does not promote replicative senescence
but rather a senescence phenotype that resembles stress-
induced (premature) senescence, which appears within a pe-
riod as short as a day after cells are exposed to stress of
chemical or physical nature that induces DNA damage (63–
65).
In support of this mechanism, our transcriptomic and
proteomic analyses revealed a strong stimulation of the
senescence pathway (including up-regulation of p21) with
the concurrent activation of the DDR in response to 20A
treatment. We found that 20A promoted a rapid activation
of two key pathways implicated in the DDR: ATM/CHK2
and ATR/CHK1. Inhibition of ATM following 20A treat-
ment reduced the senescence onset and exacerbated apop-
totic cell death, indicating that ATM functions as a linch-
pin between senescence and apoptosis. Our findings extend
previous evidence that ATM is required for survival of can-
cer cells that undergo premature senescence in response to
DNA damage agents and oxidative stress conditions (i.e.
doxorubicin, camptothecin and hydrogen peroxide) (66).
ATM has been shown to regulate metabolic reprogram-
ming in cancer cells (by controlling the levels of glucose and
glutamine) to prevent bypass of senescence (67). Here, we
showed that in response to 20A, senescence is accompanied
by up-regulation of p21 and both processes occur in a p53-
independent manner. A growing body of evidence suggests
that in addition to p53, alternative pathways downstream of
ATM (e.g. cyclin-dependent kinase inhibitors, CHK2 and
C-MYC) control senescence mediated by ATM (59,66–69).
A number of p53-independent pathways are also involved
in the transcriptional induction of p21 and its stability (e.g.
transcription factors including SP1, SP2, AP2 and STAT1
as well as signaling pathways governed by CHK2, JNK,
p38 and AKT) and this might contribute to p21-mediated
senescence (68,70,71). Of note, we found that ATM reg-
ulates senescence through both autophagy-dependent and
autophagy-independent mechanisms as disruption of au-
tophagy following 20A treatment only partially inhibited
senescence. Further studies are required to shed light on
the precise network that underlies senescence induced byG4
ligands such as 20A.
Interestingly, it was reported that the cell sensitivity toG4
ligands is correlated with the basal level of DNA damage
and telomere deprotection (11).Moreover, someG4 ligands
preferentially target cancer cells deficient forDNA repair, as
shown specifically for cells harboring BRCA1 and BRCA2
mutations (15,72). In the latter study, inhibition of DNA re-
pair using a PARP inhibitor enhanced the antitumor effect
of G4 ligand RHPS4 in vitro and in tumor xenografts (51).
In the same vein, evidence indicates that a dual G4/PARP
ligand has a significant antiproliferative potential in cancer
cells (52). Collectively, these data support the idea that the
modulation of DDR can influence the susceptibility of cells
to the cytotoxic effect of a G4 ligand.
In a transcriptome analysis, we found that 20A caused
an enrichment of the lysosomal regulatory pathways (i.e.
the MTOR and Protein Secretion Hallmarks as well as the
KEGG pathway REGULATION OF AUTOPHAGY). In
particular, this analysis provides evidence that ATM ac-
tivation is responsible for the induction of autophagy by
20A. Such regulation of autophagy has been previously re-
ported in response to other DNA damage agents and may
constitute a mechanism through which ATM enables cells
to escape death by entering senescence (74,75). In keeping
with this scenario, we found that disruption of autophagy
by deletion of either of two key autophagy genes, ATG5
or ATG7, directed cells toward apoptosis instead of senes-
cence. The relationship between autophagy and senescence
is complex as in some settings autophagy accelerates the es-
tablishment of the senescence phenotype, whereas in other
circumstances autophagy impedes this process (32,76). The
activation of autophagic flux and the up-regulation of the
autophagy receptor p62 by 20A support the idea that au-
tophagy participates in changes in metabolism and exten-
sive cellular remodeling that occur during cellular senes-
cence, amechanism thatmay confer cell adaptation toDNA
damage (34). In addition, we found that 20A promoted ac-
tivation of AMPK with a concurrent inhibition of MTOR
activity, two pathways that link autophagy to metabolism
and DDR (34). Further investigation is required to deter-
mine the exact mechanism through which autophagy oper-
ates to maintain the integrity of senescent cells treated with
20A.
Although the induction of senescence by chemo- or ra-
diotherapies was initially considered as a tumor-suppressive
mechanism, emerging evidence supports the notion that this
response can also promote tumorigenesis (76). In contrast
to apoptotic cells, senescent cells are viable and have the
ability to influence tumor growth as well as tumor response
to treatment by secretion of pro-inflammatory and mito-
genic factors (76). Whether or not 20A promotes the secre-
tion of such factors warrant further investigation.
We found that the activation of autophagy by 20A reg-
ulates DDR through the stabilization of CHK1 phospho-
rylated at Ser 345; this phosphorylation is known to co-
ordinate the DDR and the cell-cycle checkpoint response
(77). Deficiency in autophagy coupled with 20A treat-
ment led to failure in CHK1 activation and was associated
with increased levels of H2AX. Similar results were ob-
served upon loss of ATM suggesting that CHK1 stability is
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also regulated by ATM. Such interplay between ATM and
ATR/CHK1 has been also reported in response to some
DNA damage agents (78). Our data are in line with a recent
study showing that autophagy-deficient cells have impaired
homologous recombination through a mechanism that in-
volves proteasome degradation of phospho-CHK1 (61). In-
terestingly, the dephosphorylation of CHK1 has been also
reported inA549 cells treatedwith theG4 ligand 12459 (79).
The phosphatase PPM1D (also known asWIP1) was shown
to be responsible for CHK1 inactivation in cell treated with
G4L 12459.
Autophagy induction by G4 ligands Ant1,5, SYUIQ-5
and CX-5461, three compounds unrelated to 20A, was pre-
viously reported (13,36,37). Zaffaroni et al. showed that
Ant1,5 causes cell growth arrest, increased p21 expression
and induction of cytoprotective autophagy in cells (13). It
is noteworthy that these responses occurred without induc-
tion of senescence, which is different from the mechanism
identified here for 20A. The G4 ligand SYUIQ-5 causes
cell death through amechanism that depends on autophagy
(37). This suggests that the activation of autophagy in re-
sponse to a G4 ligand can have different cellular outcomes
that may be related to the chemical properties of the com-
pound, the concentration used, and the specific signaling
pathways activated by the ligand. Further investigations
are required to decipher the context-dependent role of au-
tophagy in response to different classes ofG4 ligands.Given
that the mechanism underlying the regulation of autophagy
by G4 ligands is yet not understood, it will be interesting to
determine if this regulation relies on binding of the ligand
to particular G4 structures.
Collectively, our data provide evidence for the antiprolif-
erative effects of 20A in cancer models in vivo and in vitro.
Our study also revealed that targeting of the ATM and au-
tophagy pathways is a promising strategy to achieve the
optimal efficiency of this G4 ligand in cancer cells. This
property and its p53-independent effects on senescence and
caspase-driven apoptotic cell death underline the therapeu-
tic potential of 20A in a large panel of tumors.
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